SABCS

The study, which evaluated data from 65,000 women on 21 genes, identified new risk genes and those that confer no risk, and the findings may have clinical implications.

Progression-free and overall survival seen in the veliparib arm weren't statistically significant, but were encouraging enough to move the drug to Phase III, AbbVie said.

San Antonio River Walk

Using sequencing approaches, researchers are learning more about what drives breast cancer metastasis and resistance.

In a large DCIS cohort, researchers showed the ability of Oncotype DX score to assess recurrence risk in patients treated with breast conservation surgery.

At SABCS, researchers reported on the use of biomarkers to try to predict subpopulations of TNBC patients likely to respond to platinum-based drugs.

Early data presented at SABCS suggests that ER/PR-positive breast cancer patients could respond particularly well to Genentech's PI3 kinase inhibitor.

At SABCS, researchers presented early data on immune-related biomarkers that with further validation may help identify responders to various oncologics.

Originally published Dec. 12. SAN ANTONIO, TEX. – Fifteen years after it came on the market, Herceptin is still the poster child for personalized medicine, and when combined with chemotherapy it's still the standard of care for HER2-positive breast cancer.

At the San Antonio Breast Cancer Symposium last week, Myriad Genetics presented new data on its myRisk Hereditary Cancer panel, which the firm believes will help it convince physicians, patients, and payors of the advantages of multi-gene panels over single disease testing.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.